Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Amzell B.V

    Client Virtual Booth

    AMZELL B.V

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Amzell B.V
    Netherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Siriusdreef 41 2132WT Hoofddorp, Netherlands
    Telephone
    Telephone
    +31 23 55 60 465
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amzell.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Amzell B.V. and Amring Pharmaceuticals Inc. Attending 2021 American Epilepsy
    Amzell B.V. and Amring Pharmaceuticals Inc. Attending 2021 American Epilepsy

    https://www.businesswire.com/news/home/20211202005641/en/Amzell-B.V.-and-Amring-Pharmaceuticals-Inc.-Attending-2021-American-Epilepsy-Society-Meeting-in-Chicago

    BUSINESSWIRE
    02 Dec 2021
    Share Share
    Amzell, Amring's AMZ002 Enters Phase III Trial for Infantile Epileptic Disease
    Amzell, Amring's AMZ002 Enters Phase III Trial for Infantile Epileptic Disease

    https://www.businesswire.com/news/home/20211119005740/en

    BUSINESSWIRE
    19 Nov 2021
    Share Share
    Amzell,B.V., in Collaboration With Amring Pharmaceuticals Inc. Announce
    Amzell,B.V., in Collaboration With Amring Pharmaceuticals Inc. Announce

    https://www.businesswire.com/news/home/20211119005740/en/Amzell-B.V.-in-Collaboration-With-Amring-Pharmaceuticals-Inc.-Announce-Their-Lead-Product-Has-Entered-Phase-III-Clinical-Trial-in-the-U.S.-for-Treatment-of-Infantile-Epileptic-Disease

    BUSINESSWIRE
    19 Nov 2021
    Share Share
    Amzell to begin phase 3 trial of AMZ002 to treat infantile epileptic disease
    Amzell to begin phase 3 trial of AMZ002 to treat infantile epileptic disease

    http://www.pharmabiz.com/NewsDetails.aspx?aid=133783&sid=2

    PHARMABIZ
    27 Nov 2020
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search